U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula Ca
Molecular Weight 40.078
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of CALCIUM CATION

SMILES

[Ca++]

InChI

InChIKey=BHPQYMZQTOCNFJ-UHFFFAOYSA-N
InChI=1S/Ca/q+2

HIDE SMILES / InChI

Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred
PubMed

PubMed

TitleDatePubMed
Studies on the calcemic effect of intravenous secretin in humans.
1975 Jun
Ni2+ transport by the human Na+/Ca2+ exchanger expressed in Sf9 cells.
1999 May
Aluminum is a weak agonist for the calcium-sensing receptor.
1999 May
Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein.
1999 Nov
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity.
1999 Sep 20
Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells.
2000 Aug
Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density.
2000 Aug
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.
2000 Dec
Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation.
2000 Jan 15
NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways.
2000 Jul 17
Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells.
2000 Jun
Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors.
2000 Nov
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin.
2000 Nov
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.
2000 Nov 10
Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.
2001 Aug 28
Complement activation in factor D-deficient mice.
2001 Dec 4
Molecular and functional characterization of a family of rat brain T-type calcium channels.
2001 Feb 9
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.
2001 Feb 9
Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B.
2001 Jun
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components.
2001 Jun
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.
2001 Mar 15
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities.
2001 Nov
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism.
2001 Nov
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors.
2001 Nov 1
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.
2001 Oct 26
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.
2001 Sep
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.
2001 Sep
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells.
2002 Feb
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit.
2002 Sep
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death.
2002 Sep 6
A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs.
2002 Sep 6
Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial.
2015 Aug 12
Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
2015 Sep 16
Lactose behaviour in the presence of lactic acid and calcium.
2016 Aug
Patents

Sample Use Guides

Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:07:09 GMT 2025
Edited
by admin
on Mon Mar 31 18:07:09 GMT 2025
Record UNII
2M83C4R6ZB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCIUM CATION
Common Name English
CA2+
Preferred Name English
CALCIUM(2+)
Systematic Name English
CALCIUM (II) ION
Common Name English
CALCIUM(2+) ION
Common Name English
CALCIUM ION(2+)
Common Name English
CALCIUM, ION(CA2+)
Common Name English
CALCIUM ION
Common Name English
Classification Tree Code System Code
LOINC 13959-2
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 53087-3
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 83064-6
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
WHO-ATC A12AA07
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
NCI_THESAURUS C68241
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 49936-8
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 53139-2
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 50837-4
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 59472-1
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 17863-2
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 12180-6
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
NDF-RT N0000184168
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 14415-4
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
WHO-ATC A12AA20
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
NCI_THESAURUS C597
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 41645-3
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 57333-7
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 17864-0
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 38230-9
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 34581-9
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 46093-1
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 41644-6
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 47596-2
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 49935-0
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 54367-8
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 53138-4
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 53140-0
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 59470-5
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 42567-8
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 54366-0
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 59471-3
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 53088-1
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 1994-3
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 47598-8
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 1995-0
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 59473-9
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 50838-2
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 41646-1
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
LOINC 19072-8
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
Code System Code Type Description
CHEBI
39123
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
NDF-RT
N0000009252
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY Increased Coagulation Factor Activity [PE]
DAILYMED
2M83C4R6ZB
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
FDA UNII
2M83C4R6ZB
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
CHEBI
39099
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
EPA CompTox
DTXSID7037638
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
EVMPD
SUB121174
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
CHEBI
29108
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
DRUG BANK
DB14577
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
SMS_ID
100000144534
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
NDF-RT
N0000166192
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY Cations, Divalent [Chemical/Ingredient]
CHEBI
39124
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
NCI_THESAURUS
C61660
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
RXCUI
1316581
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY RxNorm
CAS
14127-61-8
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
PUBCHEM
271
Created by admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY